The global market for Human Microbiome Based Drugs and Diagnostics was valued at US$ 1006 million in the year 2024 and is projected to reach a revised size of US$ 1981 million by 2031, growing at a CAGR of 10.3% during the forecast period.

Human Microbiome Based Drugs and Diagnostics Market

The modern approach involves exploiting the interaction between humans and the bacteria that live in or on the body to develop new drugs and therapies to treat chronic diseases such as diabetes. These microbiomes derived drugs help the physician in better diagnosis of the illness.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Human Microbiome Based Drugs and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Microbiome Based Drugs and Diagnostics.

The Human Microbiome Based Drugs and Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Microbiome Based Drugs and Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Human Microbiome Based Drugs and Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Human Microbiome Based Drugs and Diagnostics Market Report

Report Metric	Details
Report Name	Human Microbiome Based Drugs and Diagnostics Market
Accounted market size in year	US$ 1006 million
Forecasted market size in 2031	US$ 1981 million
CAGR	10.3%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Therapeutics Diagnostics
Segment by Application	Clinical Research Institutes Hospital Surgical Centers Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Second Genome, Enterome Bioscience, Yakult, Dowdupont, Vedanta BioSciences, Metabiomics Corporation, ViThera Pharmaceuticals, MicroBiome Therapeutics, Osel, Merck
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Microbiome Based Drugs and Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Human Microbiome Based Drugs and Diagnostics Market growing?

Ans: The Human Microbiome Based Drugs and Diagnostics Market witnessing a CAGR of 10.3% during the forecast period 2025-2031.

What is the Human Microbiome Based Drugs and Diagnostics Market size in 2031?

Ans: The Human Microbiome Based Drugs and Diagnostics Market size in 2031 will be US$ 1981 million.

Who are the main players in the Human Microbiome Based Drugs and Diagnostics Market report?

Ans: The main players in the Human Microbiome Based Drugs and Diagnostics Market are Second Genome, Enterome Bioscience, Yakult, Dowdupont, Vedanta BioSciences, Metabiomics Corporation, ViThera Pharmaceuticals, MicroBiome Therapeutics, Osel, Merck

What are the Application segmentation covered in the Human Microbiome Based Drugs and Diagnostics Market report?

Ans: The Applications covered in the Human Microbiome Based Drugs and Diagnostics Market report are Clinical Research Institutes, Hospital, Surgical Centers, Others

What are the Type segmentation covered in the Human Microbiome Based Drugs and Diagnostics Market report?

Ans: The Types covered in the Human Microbiome Based Drugs and Diagnostics Market report are Therapeutics, Diagnostics

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Human Microbiome Based Drugs and Diagnostics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Therapeutics

1.2.3 Diagnostics

1.3 Market by Application

1.3.1 Global Human Microbiome Based Drugs and Diagnostics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Clinical Research Institutes

1.3.3 Hospital

1.3.4 Surgical Centers

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Human Microbiome Based Drugs and Diagnostics Market Perspective (2020-2031)

2.2 Global Human Microbiome Based Drugs and Diagnostics Growth Trends by Region

2.2.1 Global Human Microbiome Based Drugs and Diagnostics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Human Microbiome Based Drugs and Diagnostics Historic Market Size by Region (2020-2025)

2.2.3 Human Microbiome Based Drugs and Diagnostics Forecasted Market Size by Region (2026-2031)

2.3 Human Microbiome Based Drugs and Diagnostics Market Dynamics

2.3.1 Human Microbiome Based Drugs and Diagnostics Industry Trends

2.3.2 Human Microbiome Based Drugs and Diagnostics Market Drivers

2.3.3 Human Microbiome Based Drugs and Diagnostics Market Challenges

2.3.4 Human Microbiome Based Drugs and Diagnostics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Human Microbiome Based Drugs and Diagnostics Players by Revenue

3.1.1 Global Top Human Microbiome Based Drugs and Diagnostics Players by Revenue (2020-2025)

3.1.2 Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Players (2020-2025)

3.2 Global Human Microbiome Based Drugs and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Human Microbiome Based Drugs and Diagnostics Revenue

3.4 Global Human Microbiome Based Drugs and Diagnostics Market Concentration Ratio

3.4.1 Global Human Microbiome Based Drugs and Diagnostics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Human Microbiome Based Drugs and Diagnostics Revenue in 2024

3.5 Global Key Players of Human Microbiome Based Drugs and Diagnostics Head office and Area Served

3.6 Global Key Players of Human Microbiome Based Drugs and Diagnostics, Product and Application

3.7 Global Key Players of Human Microbiome Based Drugs and Diagnostics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Human Microbiome Based Drugs and Diagnostics Breakdown Data by Type

4.1 Global Human Microbiome Based Drugs and Diagnostics Historic Market Size by Type (2020-2025)

4.2 Global Human Microbiome Based Drugs and Diagnostics Forecasted Market Size by Type (2026-2031)

5 Human Microbiome Based Drugs and Diagnostics Breakdown Data by Application

5.1 Global Human Microbiome Based Drugs and Diagnostics Historic Market Size by Application (2020-2025)

5.2 Global Human Microbiome Based Drugs and Diagnostics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Human Microbiome Based Drugs and Diagnostics Market Size (2020-2031)

6.2 North America Human Microbiome Based Drugs and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Human Microbiome Based Drugs and Diagnostics Market Size by Country (2020-2025)

6.4 North America Human Microbiome Based Drugs and Diagnostics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Human Microbiome Based Drugs and Diagnostics Market Size (2020-2031)

7.2 Europe Human Microbiome Based Drugs and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Human Microbiome Based Drugs and Diagnostics Market Size by Country (2020-2025)

7.4 Europe Human Microbiome Based Drugs and Diagnostics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Size (2020-2031)

8.2 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Size by Region (2020-2025)

8.4 Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Human Microbiome Based Drugs and Diagnostics Market Size (2020-2031)

9.2 Latin America Human Microbiome Based Drugs and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Human Microbiome Based Drugs and Diagnostics Market Size by Country (2020-2025)

9.4 Latin America Human Microbiome Based Drugs and Diagnostics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Market Size (2020-2031)

10.2 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Market Size by Country (2020-2025)

10.4 Middle East & Africa Human Microbiome Based Drugs and Diagnostics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Second Genome

11.1.1 Second Genome Company Details

11.1.2 Second Genome Business Overview

11.1.3 Second Genome Human Microbiome Based Drugs and Diagnostics Introduction

11.1.4 Second Genome Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

11.1.5 Second Genome Recent Development

11.2 Enterome Bioscience

11.2.1 Enterome Bioscience Company Details

11.2.2 Enterome Bioscience Business Overview

11.2.3 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Introduction

11.2.4 Enterome Bioscience Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

11.2.5 Enterome Bioscience Recent Development

11.3 Yakult

11.3.1 Yakult Company Details

11.3.2 Yakult Business Overview

11.3.3 Yakult Human Microbiome Based Drugs and Diagnostics Introduction

11.3.4 Yakult Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

11.3.5 Yakult Recent Development

11.4 Dowdupont

11.4.1 Dowdupont Company Details

11.4.2 Dowdupont Business Overview

11.4.3 Dowdupont Human Microbiome Based Drugs and Diagnostics Introduction

11.4.4 Dowdupont Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

11.4.5 Dowdupont Recent Development

11.5 Vedanta BioSciences

11.5.1 Vedanta BioSciences Company Details

11.5.2 Vedanta BioSciences Business Overview

11.5.3 Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Introduction

11.5.4 Vedanta BioSciences Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

11.5.5 Vedanta BioSciences Recent Development

11.6 Metabiomics Corporation

11.6.1 Metabiomics Corporation Company Details

11.6.2 Metabiomics Corporation Business Overview

11.6.3 Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Introduction

11.6.4 Metabiomics Corporation Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

11.6.5 Metabiomics Corporation Recent Development

11.7 ViThera Pharmaceuticals

11.7.1 ViThera Pharmaceuticals Company Details

11.7.2 ViThera Pharmaceuticals Business Overview

11.7.3 ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Introduction

11.7.4 ViThera Pharmaceuticals Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

11.7.5 ViThera Pharmaceuticals Recent Development

11.8 MicroBiome Therapeutics

11.8.1 MicroBiome Therapeutics Company Details

11.8.2 MicroBiome Therapeutics Business Overview

11.8.3 MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Introduction

11.8.4 MicroBiome Therapeutics Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

11.8.5 MicroBiome Therapeutics Recent Development

11.9 Osel

11.9.1 Osel Company Details

11.9.2 Osel Business Overview

11.9.3 Osel Human Microbiome Based Drugs and Diagnostics Introduction

11.9.4 Osel Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

11.9.5 Osel Recent Development

11.10 Merck

11.10.1 Merck Company Details

11.10.2 Merck Business Overview

11.10.3 Merck Human Microbiome Based Drugs and Diagnostics Introduction

11.10.4 Merck Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

11.10.5 Merck Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Metabiomics Corporation

ViThera Pharmaceuticals

Microbiome Therapeutics

Osel

Merck

List of Tables

Table 1. Global Human Microbiome Based Drugs and Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Therapeutics

Table 3. Key Players of Diagnostics

Table 4. Global Human Microbiome Based Drugs and Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Human Microbiome Based Drugs and Diagnostics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Human Microbiome Based Drugs and Diagnostics Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Human Microbiome Based Drugs and Diagnostics Market Share by Region (2020-2025)

Table 8. Global Human Microbiome Based Drugs and Diagnostics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Human Microbiome Based Drugs and Diagnostics Market Share by Region (2026-2031)

Table 10. Human Microbiome Based Drugs and Diagnostics Market Trends

Table 11. Human Microbiome Based Drugs and Diagnostics Market Drivers

Table 12. Human Microbiome Based Drugs and Diagnostics Market Challenges

Table 13. Human Microbiome Based Drugs and Diagnostics Market Restraints

Table 14. Global Human Microbiome Based Drugs and Diagnostics Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Human Microbiome Based Drugs and Diagnostics Market Share by Players (2020-2025)

Table 16. Global Top Human Microbiome Based Drugs and Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Microbiome Based Drugs and Diagnostics as of 2024)

Table 17. Ranking of Global Top Human Microbiome Based Drugs and Diagnostics Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Human Microbiome Based Drugs and Diagnostics Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Human Microbiome Based Drugs and Diagnostics, Headquarters and Area Served

Table 20. Global Key Players of Human Microbiome Based Drugs and Diagnostics, Product and Application

Table 21. Global Key Players of Human Microbiome Based Drugs and Diagnostics, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Human Microbiome Based Drugs and Diagnostics Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Type (2020-2025)

Table 25. Global Human Microbiome Based Drugs and Diagnostics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Type (2026-2031)

Table 27. Global Human Microbiome Based Drugs and Diagnostics Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Application (2020-2025)

Table 29. Global Human Microbiome Based Drugs and Diagnostics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Application (2026-2031)

Table 31. North America Human Microbiome Based Drugs and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Human Microbiome Based Drugs and Diagnostics Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Human Microbiome Based Drugs and Diagnostics Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Human Microbiome Based Drugs and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Human Microbiome Based Drugs and Diagnostics Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Human Microbiome Based Drugs and Diagnostics Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Human Microbiome Based Drugs and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Human Microbiome Based Drugs and Diagnostics Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Human Microbiome Based Drugs and Diagnostics Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Market Size by Country (2026-2031) & (US$ Million)

Table 46. Second Genome Company Details

Table 47. Second Genome Business Overview

Table 48. Second Genome Human Microbiome Based Drugs and Diagnostics Product

Table 49. Second Genome Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025) & (US$ Million)

Table 50. Second Genome Recent Development

Table 51. Enterome Bioscience Company Details

Table 52. Enterome Bioscience Business Overview

Table 53. Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Product

Table 54. Enterome Bioscience Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025) & (US$ Million)

Table 55. Enterome Bioscience Recent Development

Table 56. Yakult Company Details

Table 57. Yakult Business Overview

Table 58. Yakult Human Microbiome Based Drugs and Diagnostics Product

Table 59. Yakult Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025) & (US$ Million)

Table 60. Yakult Recent Development

Table 61. Dowdupont Company Details

Table 62. Dowdupont Business Overview

Table 63. Dowdupont Human Microbiome Based Drugs and Diagnostics Product

Table 64. Dowdupont Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025) & (US$ Million)

Table 65. Dowdupont Recent Development

Table 66. Vedanta BioSciences Company Details

Table 67. Vedanta BioSciences Business Overview

Table 68. Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Product

Table 69. Vedanta BioSciences Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025) & (US$ Million)

Table 70. Vedanta BioSciences Recent Development

Table 71. Metabiomics Corporation Company Details

Table 72. Metabiomics Corporation Business Overview

Table 73. Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Product

Table 74. Metabiomics Corporation Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025) & (US$ Million)

Table 75. Metabiomics Corporation Recent Development

Table 76. ViThera Pharmaceuticals Company Details

Table 77. ViThera Pharmaceuticals Business Overview

Table 78. ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Product

Table 79. ViThera Pharmaceuticals Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025) & (US$ Million)

Table 80. ViThera Pharmaceuticals Recent Development

Table 81. MicroBiome Therapeutics Company Details

Table 82. MicroBiome Therapeutics Business Overview

Table 83. MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Product

Table 84. MicroBiome Therapeutics Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025) & (US$ Million)

Table 85. MicroBiome Therapeutics Recent Development

Table 86. Osel Company Details

Table 87. Osel Business Overview

Table 88. Osel Human Microbiome Based Drugs and Diagnostics Product

Table 89. Osel Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025) & (US$ Million)

Table 90. Osel Recent Development

Table 91. Merck Company Details

Table 92. Merck Business Overview

Table 93. Merck Human Microbiome Based Drugs and Diagnostics Product

Table 94. Merck Revenue in Human Microbiome Based Drugs and Diagnostics Business (2020-2025) & (US$ Million)

Table 95. Merck Recent Development

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

Table 99. Authors List of This Report

List of Figures

Figure 1. Human Microbiome Based Drugs and Diagnostics Picture

Figure 2. Global Human Microbiome Based Drugs and Diagnostics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Human Microbiome Based Drugs and Diagnostics Market Share by Type: 2024 VS 2031

Figure 4. Therapeutics Features

Figure 5. Diagnostics Features

Figure 6. Global Human Microbiome Based Drugs and Diagnostics Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Human Microbiome Based Drugs and Diagnostics Market Share by Application: 2024 VS 2031

Figure 8. Clinical Research Institutes Case Studies

Figure 9. Hospital Case Studies

Figure 10. Surgical Centers Case Studies

Figure 11. Others Case Studies

Figure 12. Human Microbiome Based Drugs and Diagnostics Report Years Considered

Figure 13. Global Human Microbiome Based Drugs and Diagnostics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Human Microbiome Based Drugs and Diagnostics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Human Microbiome Based Drugs and Diagnostics Market Share by Region: 2024 VS 2031

Figure 16. Global Human Microbiome Based Drugs and Diagnostics Market Share by Players in 2024

Figure 17. Global Top Human Microbiome Based Drugs and Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Microbiome Based Drugs and Diagnostics as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Human Microbiome Based Drugs and Diagnostics Revenue in 2024

Figure 19. North America Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Human Microbiome Based Drugs and Diagnostics Market Share by Country (2020-2031)

Figure 21. United States Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Human Microbiome Based Drugs and Diagnostics Market Share by Country (2020-2031)

Figure 25. Germany Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Human Microbiome Based Drugs and Diagnostics Market Share by Region (2020-2031)

Figure 33. China Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Human Microbiome Based Drugs and Diagnostics Market Share by Country (2020-2031)

Figure 41. Mexico Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Human Microbiome Based Drugs and Diagnostics Market Share by Country (2020-2031)

Figure 45. Turkey Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Second Genome Revenue Growth Rate in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

Figure 49. Enterome Bioscience Revenue Growth Rate in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

Figure 50. Yakult Revenue Growth Rate in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

Figure 51. Dowdupont Revenue Growth Rate in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

Figure 52. Vedanta BioSciences Revenue Growth Rate in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

Figure 53. Metabiomics Corporation Revenue Growth Rate in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

Figure 54. ViThera Pharmaceuticals Revenue Growth Rate in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

Figure 55. MicroBiome Therapeutics Revenue Growth Rate in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

Figure 56. Osel Revenue Growth Rate in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

Figure 57. Merck Revenue Growth Rate in Human Microbiome Based Drugs and Diagnostics Business (2020-2025)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions